software version 12.3 Search Results


for windows version 10.4.3.0  (MedCalc Software Ltd)
90
MedCalc Software Ltd for windows version 10.4.3.0
For Windows Version 10.4.3.0, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/for windows version 10.4.3.0/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
for windows version 10.4.3.0 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
wolfram mathematica software suite version 12.3.0  (Wolfram Research)
90
Wolfram Research wolfram mathematica software suite version 12.3.0
Wolfram Mathematica Software Suite Version 12.3.0, supplied by Wolfram Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wolfram mathematica software suite version 12.3.0/product/Wolfram Research
Average 90 stars, based on 1 article reviews
wolfram mathematica software suite version 12.3.0 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
software version 12.3.0  (MedCalc Software Ltd)
90
MedCalc Software Ltd software version 12.3.0
Software Version 12.3.0, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/software version 12.3.0/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
software version 12.3.0 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
software version 12.3 for windows  (SAS institute)
90
SAS institute software version 12.3 for windows
Software Version 12.3 For Windows, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/software version 12.3 for windows/product/SAS institute
Average 90 stars, based on 1 article reviews
software version 12.3 for windows - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cox proportional hazard model medcalculator v.12.7  (MedCalc Software Ltd)
90
MedCalc Software Ltd cox proportional hazard model medcalculator v.12.7
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Cox Proportional Hazard Model Medcalculator V.12.7, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cox proportional hazard model medcalculator v.12.7/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
cox proportional hazard model medcalculator v.12.7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
graphing software sigmaplot for windows version 12.3  (SYSTAT)
90
SYSTAT graphing software sigmaplot for windows version 12.3
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Graphing Software Sigmaplot For Windows Version 12.3, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphing software sigmaplot for windows version 12.3/product/SYSTAT
Average 90 stars, based on 1 article reviews
graphing software sigmaplot for windows version 12.3 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
version 12.3.2 for windows  (MedCalc Software Ltd)
90
MedCalc Software Ltd version 12.3.2 for windows
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Version 12.3.2 For Windows, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 12.3.2 for windows/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
version 12.3.2 for windows - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
version 12.3 statistical software  (MedCalc Software Ltd)
90
MedCalc Software Ltd version 12.3 statistical software
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Version 12.3 Statistical Software, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 12.3 statistical software/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
version 12.3 statistical software - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
animal motility software of casa system ivos htb version 12.3  (Hamilton Thorne Ltd)
90
Hamilton Thorne Ltd animal motility software of casa system ivos htb version 12.3
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Animal Motility Software Of Casa System Ivos Htb Version 12.3, supplied by Hamilton Thorne Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/animal motility software of casa system ivos htb version 12.3/product/Hamilton Thorne Ltd
Average 90 stars, based on 1 article reviews
animal motility software of casa system ivos htb version 12.3 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
data acquisition software spectrononpro version 2.123  (Resonon Inc)
90
Resonon Inc data acquisition software spectrononpro version 2.123
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Data Acquisition Software Spectrononpro Version 2.123, supplied by Resonon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/data acquisition software spectrononpro version 2.123/product/Resonon Inc
Average 90 stars, based on 1 article reviews
data acquisition software spectrononpro version 2.123 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ngen software package version 12.3.1.4  (DNASTAR)
90
DNASTAR ngen software package version 12.3.1.4
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Ngen Software Package Version 12.3.1.4, supplied by DNASTAR, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ngen software package version 12.3.1.4/product/DNASTAR
Average 90 stars, based on 1 article reviews
ngen software package version 12.3.1.4 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
med calc version 12.3  (MedCalc Software Ltd)
90
MedCalc Software Ltd med calc version 12.3
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Med Calc Version 12.3, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/med calc version 12.3/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
med calc version 12.3 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from Mantel-Cox test are indicated. Multivariate analysis using Cox proportional hazard model evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.

Journal: Journal for Immunotherapy of Cancer

Article Title: Differential gene expression of tumor-infiltrating CD8 + T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis

doi: 10.1136/jitc-2020-001294

Figure Lengend Snippet: The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from Mantel-Cox test are indicated. Multivariate analysis using Cox proportional hazard model evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.

Article Snippet: Multivariate analyzes for DSS and PFI were performed using Cox proportional hazard model (MedCalculator V.12.7, https://www.medcalc.org/ ) in comparison to the ppCD8sig (high, intermediate, low), disease stage (IV, III, II, I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female). χ 2 test was used to determine the association between the different ppCD8sig scores and disease stage, the presence of residual disease, age, gender or different CRC anatomical locations.

Techniques: RNA Sequencing